Needham Reiterates Buy on Vaxcyte, Maintains $110 Price Target

Needham analyst Joseph Stringer has reiterated a Buy rating on Vaxcyte (NASDAQ: PCVX) and maintained a price target of $110 for the stock. This endorsement reflects confidence in the company's performance and potential growth.